May 7, 2019
Ann Arbor, Mich. -- May 7, 2019 -- Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, and Talis Clinical, a leading provider of healthcare software solutions, today announced commercial release of the ACG-Perfusion™ and ACG-RemoteView™ Systems in North America. A true Perfusion Information Management System, Talis' Advanced Clinical Guidance System supports improved clinical and operational outcomes by breaking down data, technology and care team silos to create optimal collaboration and operationalize hospital best practices.
Terumo and Talis announced a strategic partnership in January 2019 which enables Terumo to distribute Talis Clinical's ACG-Perfusion and ACG-RemoteView Systems in cardiac operating rooms and intensive care units. Terumo and Talis have future plans to expand distribution of the systems globally, as well as develop a unique application for ECMO management.
Deployed in the OR, the Talis ACG-Perfusion System allows for safe and efficient care by automatically collecting all relevant perfusion data at the point of care. Hospital specific, checklist-driven protocols guide safe best practices which are easily observed and documented in patient care. ACG-Rx™ -- a technology embedded into ACG-Perfusion -- allows the clinical team to review critical parameters and set patient-specific clinical targets to optimize therapeutic delivery.
Outside the OR, ACG-RemoteView pushes clinical and operational data to the entire critical care team. For those in supervisory roles, mobile technology makes it possible to view key metrics in real-time wherever they are, while smart notifications alert them to issues that may require immediate attention.
"Despite enormous investments in technology, healthcare teams often operate in silos -- what we refer to as a 'disconnected state,'" said Gary Colister, Founder and President of Talis Clinical. "Talis' powerful ACG System optimizes the clinical workflow to center care around the patient, eliminating silos in the CVOR and CVICU."
"Technology is revolutionizing healthcare, and Terumo is constantly seeking ways to provide new value through both the products and services we provide," said Robert DeRyke, President and CEO of Terumo Cardiovascular Group. "The Talis ACG System goes beyond data management to provide smart, actionable clinical insights. It connects clinicians with data that can help them quickly assess situations and make smarter decisions."
"Healthcare needs technologies that unlock and transform data in ways that help clinicians take better care of patients," said Harish Lecamwasam, MD, Chief Innovation Officer of Talis Clinical. "Talis Clinical's ACG solutions reconnect clinicians with patients, medical devices, health data and each other. This significantly elevates how we manage patients in the cardiac operating room and intensive care unit."
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com
Talis Clinical, a leading provider of healthcare software solutions, started over 10 years ago with an initiative to build a perioperative documentation system to support safe anesthesia care. This extensive development moved from documenting complex anesthesia workflows to providing advanced clinical guidances to improve patient care in real-time at the point of care. Today Talis Clinical software solutions have expanded beyond anesthesia to the CVOR and CVICU supporting hospitals across the country.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.